# A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

> **NCT06008054** · PHASE2 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 376 (estimated)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** SI-B003
- **DRUG:** BL-B01D1
- **DRUG:** PD-1 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT06008054
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-16
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 376 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008054, "A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06008054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*